129 related articles for article (PubMed ID: 28471200)
1. [Fullerene Doxorubicin Nanotransporter for Target Interaction with mutated gene BRCA2].
Skaličková S; Löfelmann M; Gargulák M; Dočekalová M; Ruttkay-Nedecký B; Suchý P; Kepinská M; Kizek R
Klin Onkol; 2017; 30(Supplementum1):177-179. PubMed ID: 28471200
[TBL] [Abstract][Full Text] [Related]
2. [Zinc-modified Nanotransporter for Target Drug Therapy of Breast Cancer].
Skaličková S; Gargulák M; Löffelmann M; Ruttkay-Nedecký B; Kepinská M; Parák T; Kizek R
Klin Onkol; 2017; 30(Supplementum1):174-176. PubMed ID: 28471199
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-Modified Apoferritin Nanotransfer for Targeted Cytostatic Transport.
Čížek M; Gargulák M; Sehnal K; Uhlířová D; Staňková M; Dočekalová M; Ruttkay-Nedecký B; Zídková J; Kizek R
Klin Onkol; 2019; 32(3):197-200. PubMed ID: 31216851
[TBL] [Abstract][Full Text] [Related]
4. Fullerene as a doxorubicin nanotransporter for targeted breast cancer therapy: Capillary electrophoresis analysis.
Kepinska M; Kizek R; Milnerowicz H
Electrophoresis; 2018 Sep; 39(18):2370-2379. PubMed ID: 29931716
[TBL] [Abstract][Full Text] [Related]
5. [Breast Cancer in Young Women - Correlation of Clinical Histomorphological, and Molecular-genetic Features of Breast Carcinoma in Women Younger than 35 Years of Age].
Metelková A; Skálová A; Fínek J
Klin Onkol; 2017; 30(3):202-209. PubMed ID: 28612617
[TBL] [Abstract][Full Text] [Related]
6. Targeted Drug Delivery Biopolymers Effectively Inhibit Breast Tumor Growth and Prevent Doxorubicin-Induced Cardiotoxicity.
Dragojevic S; Ryu JS; Hall ME; Raucher D
Molecules; 2022 May; 27(11):. PubMed ID: 35684309
[TBL] [Abstract][Full Text] [Related]
7. Naked and Decorated Nanoparticles Containing H
Peira E; Chirio D; Sapino S; Chegaev K; Chindamo G; Salaroglio IC; Riganti C; Gallarate M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232858
[TBL] [Abstract][Full Text] [Related]
8. Folic acid magnetic nanotheranostics for delivering doxorubicin: Toxicological and biocompatibility studies on Zebrafish embryo and larvae.
Igartúa DE; Azcona PL; Martinez CS; Alonso SDV; Lassalle VL; Prieto MJ
Toxicol Appl Pharmacol; 2018 Nov; 358():23-34. PubMed ID: 30205093
[TBL] [Abstract][Full Text] [Related]
9. Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.
Yin Q; Tang L; Cai K; Tong R; Sternberg R; Yang X; Dobrucki LW; Borst LB; Kamstock D; Song Z; Helferich WG; Cheng J; Fan TM
Proc Natl Acad Sci U S A; 2016 Aug; 113(32):E4601-9. PubMed ID: 27457945
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of DNA Methylation in BRCA2 Gene Using Electrode Biochips].
Bartošík M; Bartáková D
Klin Onkol; 2017; 30(Supplementum1):149-152. PubMed ID: 28471192
[TBL] [Abstract][Full Text] [Related]
11. Cellular Mechanisms Triggered by the Cotreatment of Resveratrol and Doxorubicin in Breast Cancer: A Translational In Vitro-In Silico Model.
Vargas JE; Puga R; Lenz G; Trindade C; Filippi-Chiela E
Oxid Med Cell Longev; 2020; 2020():5432651. PubMed ID: 33204396
[TBL] [Abstract][Full Text] [Related]
12. Gold Nanosystems Covered with Doxorubicin/DNA Complexes: A Therapeutic Target for Prostate and Liver Cancer.
Giráldez-Pérez RM; Grueso E; Montero-Hidalgo AJ; Luque RM; Carnerero JM; Kuliszewska E; Prado-Gotor R
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555216
[TBL] [Abstract][Full Text] [Related]
13. pH-responsive delivery of doxorubicin from citrate-apatite nanocrystals with tailored carbonate content.
Rodríguez-Ruiz I; Delgado-López JM; Durán-Olivencia MA; Iafisco M; Tampieri A; Colangelo D; Prat M; Gómez-Morales J
Langmuir; 2013 Jul; 29(26):8213-21. PubMed ID: 23735159
[TBL] [Abstract][Full Text] [Related]
14. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
15. Zinc-Modified Nanotransporter of Doxorubicin for Targeted Prostate Cancer Delivery.
Skalickova S; Loffelmann M; Gargulak M; Kepinska M; Docekalova M; Uhlirova D; Stankova M; Fernandez C; Milnerowicz H; Ruttkay-Nedecky B; Kizek R
Nanomaterials (Basel); 2017 Dec; 7(12):. PubMed ID: 29292780
[TBL] [Abstract][Full Text] [Related]
16. Terpyridine Functionalized Cyclodextrin Nanoparticles as Carriers for Doxorubicin: Analysis of
Viale M; Bertola N; Panebianco R; Vecchio G
Anticancer Res; 2023 Dec; 43(12):5409-5414. PubMed ID: 38030189
[TBL] [Abstract][Full Text] [Related]
17. DNA-doxorubicin interaction: New insights and peculiarities.
Silva EF; Bazoni RF; Ramos EB; Rocha MS
Biopolymers; 2017 Mar; 107(3):. PubMed ID: 27718222
[TBL] [Abstract][Full Text] [Related]
18. C60 fullerene as synergistic agent in tumor-inhibitory Doxorubicin treatment.
Prylutska S; Grynyuk I; Matyshevska O; Prylutskyy Y; Evstigneev M; Scharff P; Ritter U
Drugs R D; 2014 Dec; 14(4):333-40. PubMed ID: 25504158
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy and Ovarian Stimulation in the Patients with Breast Cancer.
Lukáš D; David P; Jaromír M
Klin Onkol; 2018; 31(5):325-329. PubMed ID: 30541317
[TBL] [Abstract][Full Text] [Related]
20. Metallothionein and Superoxide Dismutase-Antioxidative Protein Status in Fullerene-Doxorubicin Delivery to MCF-7 Human Breast Cancer Cells.
Kepinska M; Kizek R; Milnerowicz H
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
